Genetic implications in patients with NAFLD
DOI:
https://doi.org/10.12775/JEHS.2024.53.015Keywords
non-alcoholic fatty liver disease, genetics, steatosisAbstract
Introduction and purpose:
Non-alcoholic fatty liver disease's growing prevalence and the complications it brings constitutes a serious problem nowadays. According to this, better understanding of mechanisms laying on the ground of its pathogenesis is a crucial factor to better understand this disease and develop interventions to counter its effects. Genetic relationships with NAFLD are known and they show great variation of mechanisms underlying their impact on subjects' metabolic state. Due to this fact the assumption that it is worth collecting these connections in one place was made, so that it is easier to navigate in them. Mostly studies refer to rodents trials, we focused on studies referred to people with NAFLD diagnosis.
Material and method:
The literature was scrutinised in the Google Scholar database, in the Pubmed database with the use of following keywords: “genetics”, “genes”, “non-alcoholic fatty liver disease”, “NAFLD”, “non-alcoholic steatohepatitis”, “NASH”.
Results:
NAFLD as a metabolic disease has many links with metabolic pathways encoded by various genes. When it comes to genetic factors, we can specify gene expression single nucleotide polymorphisms (SNP) and genes methylation. All of these aspects affect activity of coded proteins and what follows this is its impact on human metabolism. These factors have been studied in the work of other researchers.
Conclusions:
Non-alcoholic fatty liver disease's growing prevalence and the complications it brings constitutes a serious problem nowadays. Genetic relationships with NAFLD are known and they show great variation of mechanisms underlying their impact on subjects' metabolic state.
References
Zeigerer A. NAFLD - A rising metabolic disease. Mol Metab. 2021;50:101274. doi:10.1016/j.molmet.2021.101274
Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. doi:10.1016/S2468-1253(22)00165-0
Shah PA, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: The growing challenge. Hepatology. 2023;77(1):323-338. doi:10.1002/hep.32542
Yahoo N, Dudek M, Knolle P, Heikenwälder M. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. J Hepatol. 2023;79(2):538-551. doi:10.1016/j.jhep.2023.02.033
Osorio-Conles Ó, Vega-Beyhart A, Ibarzabal A, et al. A Distinctive NAFLD Signature in Adipose Tissue from Women with Severe Obesity. Int J Mol Sci. 2021;22(19):10541. doi:10.3390/ijms221910541
von Loeffelholz C, Pfeiffer AFH, Lock JF, et al. ANGPTL8 (Betatrophin) is Expressed in Visceral Adipose Tissue and Relates to Human Hepatic Steatosis in Two Independent Clinical Collectives. Horm Metab Res. 2017;49(5):343-349. doi:10.1055/s-0043-102950
Tutunchi H, Ostadrahimi A, Saghafi-Asl M, et al. Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple-blind randomized controlled clinical trial. J Cell Physiol. 2021;236(1):417-426. doi:10.1002/jcp.29870
Pettinelli P, Arendt BM, Teterina A, et al. Altered hepatic genes related to retinol metabolism and plasma retinol in patients with non-alcoholic fatty liver disease. PLoS One. 2018;13(10):e0205747. doi:10.1371/journal.pone.0205747
Yaskolka Meir A, Keller M, Müller L, et al. Effects of lifestyle interventions on epigenetic signatures of liver fat: Central randomized controlled trial. Liver Int. 2021;41(9):2101-2111. doi:10.1111/liv.14916
Lin YC, Chang PF, Chang MH, Ni YH. A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children. Am J Clin Nutr. 2013;97(2):326-331. doi:10.3945/ajcn.112.046417
Lin YC, Chang PF, Chang MH, Ni YH. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr. 2014;99(4):869-874. doi:10.3945/ajcn.113.079749
Kitamoto T, Kitamoto A, Yoneda M, et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet. 2013;132(7):783-792. doi:10.1007/s00439-013-1294-3
Vilar-Gomez E, Pirola CJ, Sookoian S, et al. Impact of the Association Between PNPLA3 Genetic Variation and Dietary Intake on the Risk of Significant Fibrosis in Patients With NAFLD. Am J Gastroenterol. 2021;116(5):994-1006. doi:10.14309/ajg.0000000000001072
Tutunchi H, Ostadrahimi A, Saghafi-Asl M, et al. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes. Pharmacol Res. 2020;156:104770. doi:10.1016/j.phrs.2020.104770
Tauriainen MM, Männistö V, Kaminska D, et al. Serum, liver and bile sitosterol and sitostanol in obese patients with and without NAFLD. Biosci Rep. 2018;38(2):BSR20171274. doi:10.1042/BSR20171274
Zhu X, Lin X, Zhang P, Liu Y, Ling W, Guo H. Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: A case-control and an intervention study. Clin Res Hepatol Gastroenterol. 2022;46(4):101843. doi:10.1016/j.clinre.2021.101843
Wang Y, Tong J, Chang B, Wang BF, Zhang D, Wang BY. Relationship of SREBP-2 rs2228314 G>C polymorphism with nonalcoholic fatty liver disease in a Han Chinese population. Genet Test Mol Biomarkers. 2014;18(9):653-657. doi:10.1089/gtmb.2014.0116
Di Costanzo A, Pacifico L, D’Erasmo L, et al. Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children. Int J Mol Sci. 2019;20(18):4444. doi:10.3390/ijms20184444
Kaliora AC, Gioxari A, Kalafati IP, Diolintzi A, Kokkinos A, Dedoussis GV. The Effectiveness of Mediterranean Diet in Nonalcoholic Fatty Liver Disease Clinical Course: An Intervention Study. J Med Food. 2019;22(7):729-740. doi:10.1089/jmf.2018.0020
Lutz SZ, Hennige AM, Peter A, et al. The Gly385(388)Arg Polymorphism of the FGFR4 Receptor Regulates Hepatic Lipogenesis Under Healthy Diet. J Clin Endocrinol Metab. 2019;104(6):2041-2053. doi:10.1210/jc.2018-01573
Nobili V, Bedogni G, Donati B, Alisi A, Valenti L. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J Med Food. 2013;16(10):957-960. doi:10.1089/jmf.2013.0043
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jakub Misiak, Martyna Kępczyk, Oliwia Kwaśniewska, Michał Urbaś, Miłosz Ojdana, Yehor Demianenko, Oliwia Czekaj, Aleksandra Kościołek, Dawid Kościołek, Kaja Surowiecka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 328
Number of citations: 0
